Market Exclusive

FORTRESS BIOTECH, INC. (NASDAQ:FBIO) Files An 8-K Other Events

FORTRESS BIOTECH, INC. (NASDAQ:FBIO) Files An 8-K Other Events

Item 8.01. Other Events.

Attached hereto as Exhibit 99.1 and incorporated herein by
reference is a presentation including an updated corporate
overview of Fortress Biotech, Inc.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits
Exhibit No. Description
99.1 Presentation of May 2017.

About FORTRESS BIOTECH, INC. (NASDAQ:FBIO)
Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company’s product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109. FORTRESS BIOTECH, INC. (NASDAQ:FBIO) Recent Trading Information
FORTRESS BIOTECH, INC. (NASDAQ:FBIO) closed its last trading session up +0.23 at 3.89 with 60,346 shares trading hands.

Exit mobile version